Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Becerra Discusses an Investigational Cellular Therapy in CRC

September 6th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses an investigational cellular therapy in colorectal cancer.

Bekaii-Saab Shares Insight on Regorafenib Updates in mCRC

August 29th 2018

Tanios Bekaii-Saab, MD, discusses the ReDOS and IMblaze370 trials with regorafenib trials in metastatic colorectal cancer.

Expert Discusses Finding the Optimal Treatment Strategy in CRC

August 25th 2018

A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.

Dr. Bekaii-Saab Discusses Regorafenib Use in mCRC

August 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Expert Highlights Latest Immunotherapy Efforts in CRC

August 23rd 2018

Michael J. Overman, MD, discusses the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.

Dr. McCollum on Frontline Therapy for Patients With Metastatic CRC

August 21st 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).

Dr. Becerra Discusses Regorafenib Dosing in Metastatic CRC

August 20th 2018

Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

August 9th 2018

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC

August 7th 2018

The FDA has granted a breakthrough therapy designation to the combination of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr. Bekaii-Saab Reflects on the Findings of the ReDOS Trial in mCRC

August 7th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.

Dr. Choti on the Role of Surgery in Rectal Cancer

August 2nd 2018

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of surgery in the treatment of patients with rectal cancer.

Healthy Lifestyle and Improved Survival Benefit in CRC

July 30th 2018

Adjuvant Therapy for Stage 2/3 Colorectal Cancer

July 30th 2018

Immunotherapy Combinations in MSI and MSS mCRC

July 30th 2018

Sequencing and Dosing for Refractory Colon Cancer

July 30th 2018

Management of Regional Colorectal Cancer Metastases

July 30th 2018

Treatment of BRAF-Mutated Metastatic Colorectal Cancer

July 30th 2018

Second-Line PFS With Combination Biologics in mCRC

July 30th 2018

mCRC: Right-Side vs Left-Side Tumors

July 30th 2018

EGFR-Targeted Therapy in Metastatic Colorectal Cancer

July 30th 2018